HRP20120134T1 - Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem - Google Patents
Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem Download PDFInfo
- Publication number
- HRP20120134T1 HRP20120134T1 HR20120134T HRP20120134T HRP20120134T1 HR P20120134 T1 HRP20120134 T1 HR P20120134T1 HR 20120134 T HR20120134 T HR 20120134T HR P20120134 T HRP20120134 T HR P20120134T HR P20120134 T1 HRP20120134 T1 HR P20120134T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- candesartan
- cilexetil
- surfactant
- active drug
- Prior art date
Links
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical group C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229960004349 candesartan cilexetil Drugs 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 238000005550 wet granulation Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 239000004094 surface-active agent Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 229920000881 Modified starch Polymers 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Abstract
Postupak dobivanja vlažno granuliranog pripravka kandesartan-cileksetila i/ili njegovih solvata ili hidrata, naznačen time što se sastoji u: a) kombiniranju kandesartan-cileksetila ili njegovih solvata ili hidrata s vodenom otopinom koja sadrži natrijev dokusat kao prvi surfaktant, te s natrijevim lauril-sulfatom kao drugim surfaktantom, tako da se kandesartan-cileksetil homogeno dispergira u otopini; b) kombiniranju navedene disperzije iz koraka (a) s najmanje jednom farmaceutskom pomoćnom tvari, po mogućnosti laktozom i/ili preželatiniranim škrobom i/ili kalcij-karboksimetilcelulozom i/ili hidroksipropilcelulozom, uz smicanje kako bi se dobilo vlažne granule; c) izbornom rešetanju i prosijavanju navedenih vlažnih granula; d) sušenju navedenih granula; e) izbornom umiješavanju drugih pomoćnih tvari; if) izbornom oblikovanju pripravka u oblike jedinica doziranja. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Postupak dobivanja vlažno granuliranog pripravka kandesartan-cileksetila i/ili njegovih solvata ili hidrata, naznačen time što se sastoji u:
a) kombiniranju kandesartan-cileksetila ili njegovih solvata ili hidrata s vodenom otopinom koja sadrži natrijev dokusat kao prvi surfaktant, te s natrijevim lauril-sulfatom kao drugim surfaktantom, tako da se kandesartan-cileksetil homogeno dispergira u otopini;
b) kombiniranju navedene disperzije iz koraka (a) s najmanje jednom farmaceutskom pomoćnom tvari, po mogućnosti laktozom i/ili preželatiniranim škrobom i/ili kalcij-karboksimetilcelulozom i/ili hidroksipropilcelulozom, uz smicanje kako bi se dobilo vlažne granule;
c) izbornom rešetanju i prosijavanju navedenih vlažnih granula;
d) sušenju navedenih granula;
e) izbornom umiješavanju drugih pomoćnih tvari; i
f) izbornom oblikovanju pripravka u oblike jedinica doziranja.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se upotrebljava vodenu otopinu prvog surfaktanta, gdje je navedeni surfaktant prisutan u koncentraciji od otprilike 1 % do 20% (tež./tež.), po mogućnosti od 2% do 8 % (tež./tež.).
3. Postupak dobivanja oblika jedinice doziranja koji sadrži kandesartan-cileksetil i/ili njegove solvate ili hidrate i najmanje jedan drugi aktivni lijek, naznačen time što se pripravak kojeg se dobiva postupkom u skladu s patentnim zahtjevima 1 i 2 kombinira s najmanje jednim drugim aktivnim lijekom i izborno dodatnim pomoćnim tvarima.
4. Postupak u skladu s patentnim zahtjevom 3, naznačen time što navedeni drugi aktivni lijek se dodaje u otopinu iz koraka (a) i/ili u smjesu iz koraka (b) i/ili u granule iz koraka (e) kako bi se kombiniralo pripravak s navedenim drugim aktivnim lijekom.
5. Vlažno granulirani farmaceutski pripravak kandesartan-cileksetila i/ili njegovih solvata ili hidrata, naznačen time što sadrži:
a) kandesartan-cileksetil, ili njegove solvate ili hidrate, predobrađen vodenom otopinom natrijevog dokusata kao prvogm surfaktanta, te natrijevim lauril-sulfatom kao drugim surfaktantom; i
b) najmanje jednu farmaceutski prihvatljivu pomoćnu tvar, dobivenu postupkom u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
6. Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što se farmaceutski prihvatljivu pomoćnu tvar bira između celuloza i celuloznih derivata, laktoze, škrobovi i škrobnih derivata, ciklodekstrina, polidekstroza, ili smjesa navedenih tvari, a po mogućnosti je se bira između hidroksipropilceluloze, laktoze i kalcij-karboksimetilceluloze, te preželatiniranog škroba.
7. Oblik jedinice doziranja kojeg se dobiva iz vlažno granuliranog pripravka u skladu s patentnim zahtjevom 5 ili 6, naznačen time što je navedeni oblik jedinice doziranja tableta ili kapsula, gdje je po mogućnosti navedeni oblik doziranja obložen.
8. Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što je navedena kombinacija surfaktanata prisutna u rasponu koncentracija od otprilike 0,1% do 10 % (tež./tež.) navedenog pripravka, po mogućnosti u rasponu od 0,5% do 5 % (tež./tež.) navedenog pripravka.
9. Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što navedeni pripravak također sadrži najmanje jedan aktivni lijek uz kandesartan-cileksetil.
10. Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što se navedeni dodatni aktivni lijek bira iz skupina diuretika, po mogućnosti hidroklortiazida, antihipertenzivnih sredstava, po mogućnosti amlodipina i njegovih soli, te inhibitora reduktaze, po mogućnosti atorvastatina i njegovih soli.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08016396A EP2165702B1 (en) | 2008-09-17 | 2008-09-17 | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120134T1 true HRP20120134T1 (hr) | 2012-03-31 |
Family
ID=40291309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120134T HRP20120134T1 (hr) | 2008-09-17 | 2012-02-10 | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2165702B1 (hr) |
| AT (1) | ATE533474T1 (hr) |
| DK (1) | DK2165702T3 (hr) |
| ES (1) | ES2377552T3 (hr) |
| HR (1) | HRP20120134T1 (hr) |
| PL (1) | PL2165702T3 (hr) |
| PT (1) | PT2165702E (hr) |
| SI (1) | SI2165702T1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5917844B2 (ja) * | 2011-06-24 | 2016-05-18 | 日本ケミファ株式会社 | カンデサルタンシレキセチル製剤 |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| EP2952187A4 (en) * | 2013-01-30 | 2016-08-17 | Sawai Seiyaku Kk | PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL |
| KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
| EP3219309A1 (en) * | 2016-03-17 | 2017-09-20 | K.H.S. Pharma Holding GmbH | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
| JP2018141011A (ja) * | 2018-05-24 | 2018-09-13 | 日本ケミファ株式会社 | カンデサルタン シレキセチル製剤 |
| KR20230000506A (ko) * | 2021-06-24 | 2023-01-03 | 주식회사 종근당 | 칸데사르탄, 암로디핀 및 아트로바스타틴을 포함하는 약제학적 복합제제 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146683B1 (de) | 1981-07-31 | 1987-11-19 | Siemens Aktiengesellschaft | Wechselrichter |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| TW284688B (hr) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| WO2002102414A1 (en) | 2001-06-14 | 2002-12-27 | Otsuka Pharmaceutical Co., Ltd. | Medicinal compositions |
| US20030114497A1 (en) | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| ITMI20012366A1 (it) | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| EP1592406A2 (en) | 2003-02-13 | 2005-11-09 | Phares Pharmaceutical Research N.V. | Lipophilic compositions |
| WO2005070398A2 (en) | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
| WO2005079751A2 (en) * | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
| WO2005084648A1 (en) | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
| KR20070118224A (ko) | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
| DK1843754T3 (da) | 2005-01-26 | 2011-11-21 | Lek Pharmaceuticals | Ny farmaceutisk sammensætning indeholdende candesartan-cilexetil som lipofilt krystallinsk stof |
| JP2008536929A (ja) | 2005-04-18 | 2008-09-11 | ルビコン・リサーチ・ピーヴィーティー・エルティーディー | 生体強化組成物 |
| EP1793801A1 (en) | 2005-07-15 | 2007-06-13 | Teva Pharmaceutical Industries Ltd. | Novel granulation process and granulate produced therefrom |
| US20090123543A1 (en) | 2006-01-02 | 2009-05-14 | Rubicon Research Private Limited | Pharmaceutical compositions |
| WO2008065097A2 (en) * | 2006-11-28 | 2008-06-05 | Laboratorios Liconsa, S.A. | Stabilized solid pharmaceutical composition of candesartan cilexetil |
| EP1961412A1 (en) * | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Self-microemulsifying drug delivery systems |
| EP1952806A1 (en) | 2007-02-01 | 2008-08-06 | Helm AG | Process for the preparation of adsorbates of candesartan |
| US20090048316A1 (en) * | 2007-03-08 | 2009-02-19 | Minutza Leibovici | Pharmaceutical composition comprising candesartan cilexetil |
| EP1997479A1 (en) | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
-
2008
- 2008-09-17 SI SI200830536T patent/SI2165702T1/sl unknown
- 2008-09-17 EP EP08016396A patent/EP2165702B1/en not_active Not-in-force
- 2008-09-17 ES ES08016396T patent/ES2377552T3/es active Active
- 2008-09-17 PL PL08016396T patent/PL2165702T3/pl unknown
- 2008-09-17 PT PT08016396T patent/PT2165702E/pt unknown
- 2008-09-17 DK DK08016396.7T patent/DK2165702T3/da active
- 2008-09-17 AT AT08016396T patent/ATE533474T1/de active
-
2012
- 2012-02-10 HR HR20120134T patent/HRP20120134T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2377552T3 (es) | 2012-03-28 |
| EP2165702A1 (en) | 2010-03-24 |
| PT2165702E (pt) | 2012-02-07 |
| EP2165702B1 (en) | 2011-11-16 |
| SI2165702T1 (sl) | 2012-05-31 |
| ATE533474T1 (de) | 2011-12-15 |
| DK2165702T3 (da) | 2012-03-05 |
| PL2165702T3 (pl) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120134T1 (hr) | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem | |
| JP4880591B2 (ja) | イルベサルタンを含む医薬組成物 | |
| KR20090055561A (ko) | 트리아졸로[4,5-ｄ]피리미딘 유도체를 포함하는 경구 투여용으로 적합한 조성물 | |
| JP6895779B2 (ja) | アジルサルタン含有固形医薬組成物 | |
| JP2009515956A (ja) | テルミサルタンの医薬組成物 | |
| BRPI0715634A2 (pt) | composiÇÕes de imatinibe | |
| TW201400145A (zh) | 含酸型羧甲基纖維素之崩壞性粒子組成物之製造方法、該組成物及含該組成物之口腔內崩壞錠劑 | |
| KR101910902B1 (ko) | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 | |
| CA2720744A1 (en) | Granulation of active pharmaceutical ingredients | |
| EP1994926B9 (en) | Valsartan formulations | |
| WO2008045006A1 (en) | Formulations of candesartan | |
| JP6302802B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| PL236001B1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
| JP2014037356A (ja) | カンデサルタンシレキセチル経口製剤 | |
| CN109481437B (zh) | 一种氯沙坦钾药物制剂 | |
| JP6076406B2 (ja) | カンデサルタンシレキセチル製剤 | |
| JP2009533461A (ja) | ２−アザ−ビシクロ［３．３．０］−オクタン−３−カルボン酸誘導体の安定な医薬組成物 | |
| JP4698000B2 (ja) | 水易溶性薬物含有錠剤 | |
| JP5917844B2 (ja) | カンデサルタンシレキセチル製剤 | |
| JP6346314B2 (ja) | カンデサルタン シレキセチル製剤 | |
| JP6272328B2 (ja) | カンデサルタンシレキセチル含有製剤 | |
| CN101912390A (zh) | 含厄贝沙坦的药用组合物 | |
| WO2015199115A1 (ja) | 経口投与用医薬組成物 | |
| JP2018141011A (ja) | カンデサルタン シレキセチル製剤 | |
| KR102362787B1 (ko) | 리바록사반 함유 고체분산체 및 이의 제조방법 |